| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-09-10 | Keytruda® (pembrolizumab) | locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy (post-platinum failure) | 3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2017-09-09 | lasmiditan | migraine | 3 | Eli Lilly (USA - IN) | CNS diseases - Neurological diseases |
| 2017-09-09 | Cabometyx™ (cabozantinib) | previously untreated advanced renal cell carcinoma (RCC) | 2 | Exelixis (USA - CA) | Cancer - Oncology |
| 2017-09-09 | epacadostat and Keytruda® (pembrolizumab) | melanoma | 3 | Incyte (USA - DE) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2017-09-08 | pembrolizumab | advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma | 2 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2017-09-08 | tisotumab vedotin (HuMax-TF-ADC) | solid tumors (ovarian cancer, cervical cancer, endometrium cancer, bladder cancer, prostate cancer, esophageal cancer, lung cancer) | 1-2 | Genmab (Denmark) | Cancer - Oncology |
| 2017-09-08 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | pancreatic cancer | 2 | Erytech Pharma (France) | Cancer - Oncology |
| 2017-09-07 | givosiran (ALN-AS1) | hepatic porphyrias, including acute intermittent porphyria (AIP) | 1 | Alnylam Pharmaceuticals (USA - MA) | Rare diseases - Metabolic diseases |
| 2017-09-07 | upadacitinib (ABT-494) | atopic dermatitis | 2 | Abbvie (USA - IL) | Autoimmune diseases - Dermatological diseases |
| 2017-09-07 | VK2809 | glycogen storage disease type Ia (GSD Ia) | preclinical | Viking Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Liver diseases |
| 2017-09-07 | IFX-1 | moderate to severe Hidradenitis Suppurativa (HS) | 2a | InflaRx (Germany) | Dermatological diseases - Inflammatory diseases |
| 2017-09-06 | AAI101 and cefepime | complicated urinary tract infections (cUTI) | 2 | Allecra Therapeutics (France - Germany) | Infectious diseases |
| 2017-09-06 | AllerT | birch pollen allergy | 2b | Anergis (Switzerland) | Allergic diseases - Immunological diseases |
| 2017-09-06 | PXS-5382A | idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions including non-alcoholic steatohepatitis (NASH), kidney fibrosis and heart fibrosis | 1 | Synairgen (UK) | Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases |
| 2017-09-06 | MTL-CEBPA - CEBPA-51 | preclinical | Mina Therapeutics (UK) | Cancer - Oncology - Liver diseases - Hepatic diseases | |
| 2017-09-06 | DS-1211 | 1 | Daiichi Sankyo (Japan) Sanford Burnham Prebys Medical Discovery Institute (USA - CA) | ||
| 2017-09-05 | QGC001 | arterial hypertension | 2 | Quantum Genomics (France) | Cardiovascular diseases |
| 2017-09-05 | Arikayce® (amikacin sulfate - liposomal amikacin for inhalation) | treatment-refractory Nontuberculous Mycobacterial (NTM) lung disease caused by Mycobacterium Avium Complex (M | 3 | Insmed Limited (USA - NJ) | Infectious diseases |
| 2017-09-05 | B12019 - pegfilgrastim - biosimilar version of Neulasta® | chemotherapy induced neutropenia | 1 | Cinfa Biotech (Spain) | Cancer - Oncology |
| 2017-09-05 | B12019 - pegfilgrastim - biosimilar version of Neulasta® | chemotherapy induced neutropenia. | 1 | Cinfa Biotech (Spain) | Cancer - Oncology |
